$MEIP
MEI Pharma, Inc.

2013 Q1 Form 10-Q Financial Statement

#000119312513050392 Filed on February 12, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2012 Q4 2012 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.230M $1.420M $880.0K
YoY Change 51.85% 57.78% 8.64%
% of Gross Profit
Research & Development $1.543M $1.338M $1.320M
YoY Change 3.56% 26.11% 247.37%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $0.00
YoY Change 0.0%
% of Gross Profit
Operating Expenses $2.768M $2.756M $2.200M
YoY Change 20.3% 40.83% 84.87%
Operating Profit -$2.768M -$2.756M
YoY Change 20.3% 40.83%
Interest Expense $20.00K $0.00 $100.0K
YoY Change -33.33% -100.0% -122.22%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.750M -$2.750M -$2.100M
YoY Change 21.15% 78.57% 28.05%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.753M -$2.754M -$2.101M
YoY Change 21.33% 78.72% 27.95%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$183.1K -$503.7K -$660.4K
COMMON SHARES
Basic Shares Outstanding 15.02M shares 21.67M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q1 2012 Q4 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.20M $26.90M $6.200M
YoY Change 796.3% 438.0% 58.97%
Cash & Equivalents $24.17M $26.88M $6.202M
Short-Term Investments
Other Short-Term Assets $300.0K $200.0K $100.0K
YoY Change -40.0% 0.0% -66.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $24.43M $27.07M $6.348M
YoY Change 640.21% 420.65% 53.7%
LONG-TERM ASSETS
Property, Plant & Equipment $41.00K $22.00K $25.00K
YoY Change -34.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $520.0K $510.0K $25.00K
YoY Change -34.21%
TOTAL ASSETS
Total Short-Term Assets $24.43M $27.07M $6.348M
Total Long-Term Assets $520.0K $510.0K $25.00K
Total Assets $24.95M $27.58M $6.373M
YoY Change 655.97% 430.46% 52.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $528.0K $448.0K $594.0K
YoY Change 32.0% 12.0% 81.1%
Accrued Expenses $1.254M $1.349M $1.180M
YoY Change 14.0% 49.89% 28.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.782M $1.797M $1.774M
YoY Change 18.8% 38.23% -25.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.782M $1.797M $1.774M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.800M $1.800M $1.774M
YoY Change 20.0% 38.46% -25.27%
SHAREHOLDERS EQUITY
Retained Earnings -$93.08M -$90.33M -$85.11M
YoY Change 9.7%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.17M $25.79M $4.599M
YoY Change
Total Liabilities & Shareholders Equity $24.95M $27.58M $6.373M
YoY Change 655.97% 430.46% 52.9%

Cashflow Statement

Concept 2013 Q1 2012 Q4 2012 Q2
OPERATING ACTIVITIES
Net Income -$2.753M -$2.754M -$2.101M
YoY Change 21.33% 78.72% 27.95%
Depreciation, Depletion And Amortization $10.00K $10.00K $0.00
YoY Change 0.0%
Cash From Operating Activities -$2.630M -$2.160M -$1.300M
YoY Change 15.35% 22.03% -20.25%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$30.00K $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.800M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -60.00K 25.33M 4.790M
YoY Change 1185.79% 648.44%
NET CHANGE
Cash From Operating Activities -2.630M -2.160M -1.300M
Cash From Investing Activities -30.00K 0.000 0.000
Cash From Financing Activities -60.00K 25.33M 4.790M
Net Change In Cash -2.720M 23.17M 3.490M
YoY Change 19.3% 11485.0% -452.53%
FREE CASH FLOW
Cash From Operating Activities -$2.630M -$2.160M -$1.300M
Capital Expenditures -$30.00K $0.00 $0.00
Free Cash Flow -$2.600M -$2.160M -$1.300M
YoY Change 14.04% 22.03% -20.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q2 us-gaap Share Price
SharePrice
5.34
CY2012Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
7.14
CY2012Q2 meip Class Of Warrant Or Right Common Stock Exchange Ratio
ClassOfWarrantOrRightCommonStockExchangeRatio
0.0833 pure
CY2012Q2 meip Weighted Average Discount Rate
WeightedAverageDiscountRate
0.10 pure
CY2013Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15015454 shares
CY2012Q4 meip Reverse Stock Split Ratio
ReverseStockSplitRatio
6 pure
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4991000
CY2012Q1 meip Common Stock Issuable Upon Exercise Of Warrants
CommonStockIssuableUponExerciseOfWarrants
0.04167 shares
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
197000
CY2012Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
433000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
120948 shares
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
25787000
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
488000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.02
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15015454 shares
CY2012Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4639061 shares
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
448000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90329000
CY2012Q4 us-gaap Assets
Assets
27584000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.32
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27584000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26877000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15015454 shares
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1349000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1797000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
287059 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2012Q4 us-gaap Assets Current
AssetsCurrent
27074000
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
3.12
CY2012Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
89710000
CY2012Q2 meip Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y
us-gaap Operating Income Loss
OperatingIncomeLoss
-3890000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
406000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5043000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
116116000
CY2012Q4 meip Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y10M24D
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3858000
CY2012Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
146000
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
4599000
CY2012Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2012Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3416491 shares
CY2012Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
594000
CY2012Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2012Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85111000
CY2012Q2 us-gaap Assets
Assets
6373000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.64
CY2012Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6373000
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6202000
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3416491 shares
CY2012Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1180000
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1774000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
143926 shares
CY2012Q2 us-gaap Common Stock Value
CommonStockValue
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2012Q2 us-gaap Assets Current
AssetsCurrent
6348000
CY2012Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0090 pure
us-gaap Share Based Compensation
ShareBasedCompensation
256000
us-gaap Profit Loss
ProfitLoss
-3153000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.76
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3504000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
5000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1133000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.45 pure
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1785000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-72000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2105000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4637000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.48 pure
us-gaap Operating Expenses
OperatingExpenses
3890000
us-gaap Financial Services Costs
FinancialServicesCosts
406000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1788720 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0132 pure
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
53000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1399697 shares
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
1139000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.58
dei Trading Symbol
TradingSymbol
MEIP
dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001262104
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
us-gaap Operating Income Loss
OperatingIncomeLoss
-5222000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25326000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0062 pure
us-gaap Share Based Compensation
ShareBasedCompensation
580000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.00
us-gaap Profit Loss
ProfitLoss
-5218000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.17
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Stock Issued1
StockIssued1
500000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Concentration of Credit Risk</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains accounts in federally insured financial institutions in excess of federally insured limits. However, management believes that the Company is not exposed to significant credit risk due to the financial positions of the depository institutions in which these deposits are held.</font></p> </div>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4647000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
5000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
20675000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.53 pure
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2332000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
51000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
143133 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2890000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25326000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.61 pure
us-gaap Operating Expenses
OperatingExpenses
5222000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4477460 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0078 pure
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-146000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5461800 shares
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
10734
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
meip Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
P4Y8M12D
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosures made in the accompanying notes to the consolidated financial statements. The Company uses estimates for certain accruals including clinical and pre-clinical study fees and expenses, share-based compensation, and valuations of derivative liabilities, among others. Actual results could differ from those estimates.</font></p> </div>
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
169000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.47
meip Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodTotalIntrinsicValue
meip Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2013-04
meip Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue
meip Estimated Useful Life Of Intangible Assets
EstimatedUsefulLifeOfIntangibleAssets
14 Y
meip Percentage Of Likelihood Of Income Tax Being Sustained
PercentageOfLikelihoodOfIncomeTaxBeingSustained
0.50 pure
CY2012Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4800000
CY2012Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
971700 shares
CY2012Q2 meip Stock Issued During Period Shares Common Stock Warrants
StockIssuedDuringPeriodSharesCommonStockWarrants
485859 shares
CY2012Q2 meip Class Of Warrant Or Right Exercise Period
ClassOfWarrantOrRightExercisePeriod
P5Y
CY2012Q2 meip Warrants Conversion Premium Percentage
WarrantsConversionPremiumPercentage
0.20 pure
CY2012Q3 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
195756 shares
CY2000Q4 meip Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2000-12
CY2012Q1 meip Number Of Warrants In Each Unit
NumberOfWarrantsInEachUnit
1 shares
CY2012Q1 meip Number Of Shares Of Common Stock In Each Unit
NumberOfSharesOfCommonStockInEachUnit
0.0833 shares
CY2012Q3 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
500000
us-gaap Operating Income Loss
OperatingIncomeLoss
-93596000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
406000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
112260000
us-gaap Gain Loss On Investments
GainLossOnInvestments
100000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
45000
us-gaap Share Based Compensation
ShareBasedCompensation
3371000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-508000
us-gaap Profit Loss
ProfitLoss
-90329000
us-gaap Stock Issued1
StockIssued1
500000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-85587000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
2904000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
26877000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25102000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
197000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46994000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
112519000
us-gaap Operating Expenses
OperatingExpenses
93596000
us-gaap Financial Services Costs
FinancialServicesCosts
406000
us-gaap License Costs
LicenseCosts
21500000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
448000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000
us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
1188000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
665000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1349000
CY2012Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2756000
CY2012Q4 us-gaap Profit Loss
ProfitLoss
-2754000
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2012Q4 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
2000
CY2012Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1418000
CY2012Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1338000
CY2012Q4 us-gaap Operating Expenses
OperatingExpenses
2756000
CY2012Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5455444 shares
CY2011Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1957000
CY2011Q4 us-gaap Profit Loss
ProfitLoss
-1541000
CY2011Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2011Q4 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
2000
CY2011Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
896000
CY2011Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1061000
CY2011Q4 us-gaap Operating Expenses
OperatingExpenses
1957000
CY2011Q4 us-gaap Financial Services Costs
FinancialServicesCosts
9000
CY2011Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1979347 shares
CY2011Q4 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
423000

Files In Submission

Name View Source Status
0001193125-13-050392-index-headers.html Edgar Link pending
0001193125-13-050392-index.html Edgar Link pending
0001193125-13-050392.txt Edgar Link pending
0001193125-13-050392-xbrl.zip Edgar Link pending
d451190d10q.htm Edgar Link pending
d451190dex311.htm Edgar Link pending
d451190dex312.htm Edgar Link pending
d451190dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
meip-20121231.xml Edgar Link completed
meip-20121231.xsd Edgar Link pending
meip-20121231_cal.xml Edgar Link unprocessable
meip-20121231_def.xml Edgar Link unprocessable
meip-20121231_lab.xml Edgar Link unprocessable
meip-20121231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending